Clinical Trial

Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

Study acronym: PCAB-PCI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
Trial Details
NCT Number NCT07068490
Lead Sponsor Samsung Medical Center
Conditions Coronary Artery Disease
Enrollment 100,000 participants
Start Date 2024-10-22
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-16